Bifogade filer
2cureX Conducts First Direct-to-Patient IndiTreat® Test Under “Operation Twin Code” Strategy
Prenumeration
Beskrivning
| Land | Danmark |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
2cureX AB (Ticker: 2CUREX) is proud to announce a historic commercial milestone: the company has successfully sold and initiated delivery of its first IndiTreat® test through its direct-to-patient channel. This is the first time a test has been sold via 2cureX AB (Sweden) and delivered operationally by 2cureX AS (Denmark), validating the company’s dual-entity, cross-border strategy.
The test was purchased by a private colorectal cancer patient in the United Kingdom. The biopsy was collected within the publicly funded healthcare systems of the United Kingdom (NHS), and the tissue sample has now been shipped to Denmark for analysis—marking a complete activation of 2cureX’s B2C model.
Nathaniel Hutley, Interim CEO, commented:
“This is a defining moment. We’ve proven the model works: the AB made the sale, the AS is delivering the science, and the patient is at the center. We’re now live. Functional precision oncology is not just real—it’s operational.”
This milestone comes just days after the company launched “Operation Twin Code”, a cryptic and layered marketing and communications program designed to roll out across Europe. The campaign began with the message “Echoes from the North”, symbolizing the synchronized movement between Sweden and Denmark in launching a new model of patient-first cancer diagnostics.
“We’ve now entered an entirely new commercial reality,” Nathaniel Hutley added. “For investors, clinicians, and patients watching—this is not a trial balloon. This is a functioning system. And this is just the beginning.”
2cureX invites patients, clinicians, and partners to get in touch as the company expands its direct-to-patient offerings and scales across new territories.